晚期非小细胞肺癌所致血小板增多及其临床意义

Thrombocytosis in Patients with Advanced Non-small Cell Lung Cancer and Its Clinic Significance

目的探讨血小板计数与晚期非小细胞肺癌之间的关系及其临床意义。方法对147例病理及临床确诊晚期非小细胞肺癌患者在首治前采集空腹外周血1.5 ml进行周围血小板计数检查,排除药物及疾病的影响,血小板高于300×109/L为增多,所有病例均接受GP或NP方案化疗4周期,以30例同期保健科体检的健康人作为对照组。结果血小板增多发生率为48.3%,与肺癌病理学类型无关,与对照组相比差异有统计学意义。晚期非小细胞肺癌组血小板计数平均值为(358.76±146.52)×109/L明显高于对照组(204.57±52.18)×109/L。肺癌患者中,血小板增多组化疗有效率为43.7%,显著低于血小板正常组62.1%。结论血小板计数可作为晚期非小细胞肺癌辅助诊断和评估预后的一个指标。在晚期肺癌综合治疗中,要注意抗血小板治疗。

Objective To investigate the relationship between thrombocytosis and advanced non-small cell lung cancer （NSCLC） and its clinic significance. Methods One point five milliliter of peripheral blood were collected to detect the platelet counts in 147 patients with advanced NSCLC conformed by pathologic and clinic diagnosis before the treatment. Excluding the influences of medicine and disease,thrombocytosis is defined when the blood platelet count was higher than 300×109/L. All these patients accepted 4 cycles chemotherapy by GP or NP plan. The 30 healthy people who accepted routine physical examination at the same time were as control. Results Thrombocytosis was found in 48.3% of the patients. No difference was observed between histological types. The incidence of thrombocytosis in patients with NSCLC was higher than the control group. And the platelet av- erage count was （358.76 ± 146.52） ×109/L, which was higher than （204.57 ± 52.18 ）×109/L in control（ P 〈 0.05 ）. The Curative efficiency in thrombocytosis group was 43.7% ,which was lower than 62.1% in normal group among these lung cancer patients. Conclusion Platelet count can be used as an assistant index in the diagnosis and prognosis judgment of patients with advanced NSCLC. The antiplatelet therapy should be performed in the combined modality therapy of advanced lung cancer.